封面
市场调查报告书
商品编码
1698002

放射毒性治疗市场-全球产业规模、份额、趋势、机会和预测,按产品、适应症、放射类型、最终用户、地区和竞争细分,2020 年至 2030 年

Radiation Toxicity Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Indication, By Radiation Type, By End-user By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球放射毒性治疗市场价值为 24.8 亿美元,预计在预测期内将稳定成长,到 2030 年的复合年增长率为 5.40%。近年来,全球放射毒性治疗市场经历了显着的增长和演变,这得益于癌症发病率的上升以及放射疗法在癌症治疗中的应用范围的扩大。放射疗法虽然是肿瘤学中的重要工具,但会导致放射毒性,这通常需要专门的治疗和管理策略。该市场涵盖了旨在减轻和治疗放射疗法不良影响的广泛产品和服务,使其成为现代癌症治疗的重要组成部分。

市场概览
预测期 2026-2030
2024 年市场规模 24.8亿美元
2030年市场规模 34.1亿美元
2025-2030 年复合年增长率 5.40%
成长最快的领域 慢性放射综合症
最大的市场 北美洲

该市场成长的主要驱动力是全球癌症负担的增加。随着全球癌症发生率持续上升,接受放射治疗的患者数量大幅增加。然而,放射治疗并非没有副作用,包括皮肤反应、胃肠道问题和器官损伤在内的放射毒性是一个常见的问题。这刺激了对辐射毒性治疗方案的需求,包括药品、医疗设备和支持性护理服务。药品是放射毒性治疗市场的一个重要部分,其中的药物和药品旨在控制和缓解放射毒性症状。这些药物包括抗发炎剂、生长因子和放射防护药物。此外,标靶治疗和免疫调节剂的进步有望提高放射治疗的有效性,同时降低相关毒性。

主要市场驱动因素

癌症盛行率上升

主要市场挑战

认知和教育有限

主要市场趋势

放射防护药物和支持性治疗

目录

第 1 章:产品概述

第二章:研究方法

第三章:执行摘要

第 4 章:顾客之声

第五章:放射毒性治疗市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 副产物(集落刺激因子、碘化钾、普鲁士蓝二乙烯三胺五乙酸等)
    • 依适应症(急性放射综合症、慢性放射综合症)
    • 依辐射类型(电离辐射、非电离辐射)
    • 按最终使用者(医院和诊所、门诊护理中心、其他)
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第六章:北美放射毒性治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 加拿大
    • 墨西哥

第七章:欧洲放射毒性治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第八章:亚太放射毒性治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章:南美洲放射毒性治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第十章:中东与非洲放射毒性治疗市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 最新动态
  • 产品发布
  • 合併与收购

第 13 章:全球放射毒性治疗市场:SWOT 分析

第 14 章:竞争格局

  • Amgen Inc.
  • Jubilant Pharma Limited
  • Tanner Pharma Group
  • Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
  • Recipharm AB
  • Mission Pharmacal Company
  • Partner Therapeutics, Inc.
  • Novartis AG
  • Viatris Inc.
  • Coherus Biosciences Inc.

第 15 章:策略建议

第16章调查会社について・免责事项

简介目录
Product Code: 17563

Global Radiation Toxicity Treatment Market was valued at USD 2.48 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 5.40% through 2030. The Global Radiation Toxicity Treatment Market has witnessed significant growth and evolution in recent years, driven by the increasing incidence of cancer and the expanding use of radiation therapy in cancer treatment. Radiation therapy, while a crucial tool in oncology, can lead to radiation toxicity, which often necessitates specialized treatments and management strategies. This market encompasses a wide range of products and services aimed at mitigating and treating the adverse effects of radiation therapy, making it an essential component of modern cancer care.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.48 Billion
Market Size 2030USD 3.41 Billion
CAGR 2025-20305.40%
Fastest Growing SegmentChronic Radiation Syndrome
Largest MarketNorth America

The primary drivers of this market's growth is the rising global cancer burden. As cancer incidence continues to rise worldwide, the number of patients undergoing radiation therapy has increased substantially. However, radiation therapy is not without its side effects, and radiation toxicity, including skin reactions, gastrointestinal issues, and organ damage, is a common concern. This has spurred the demand for radiation toxicity treatment options, including pharmaceuticals, medical devices, and supportive care services. Pharmaceuticals form a crucial segment of the radiation toxicity treatment market, with drugs and medications developed to manage and alleviate the symptoms of radiation toxicity. These pharmaceuticals include anti-inflammatory agents, growth factors, and radioprotective drugs. Additionally, advancements in targeted therapies and immunomodulators hold promise for improving the effectiveness of radiation therapy while reducing associated toxicities.

Key Market Drivers

Increasing Cancer Prevalence

The escalating global incidence of cancer significantly propels the growth of the Radiation Toxicity Treatment Market. This surge in cancer cases leads to increased utilization of radiation therapy, consequently amplifying the demand for treatments addressing radiation-induced toxicities. Recent studies indicate a substantial rise in cancer cases worldwide. For instance, projections suggest in 2022, approximately 20 million new cancer cases were reported globally, resulting in nearly 10 million deaths. Demographic projections suggest that the annual incidence of cancer will rise to 35 million by 2050, representing a 77% increase from 2022 figures. This surge is particularly pronounced in low- and middle-income countries, where healthcare infrastructure may struggle to accommodate the growing burden.

Key Market Challenges

Limited Awareness and Education

One of the primary challenges is the lack of awareness among patients undergoing radiation therapy. For many individuals diagnosed with cancer, the focus understandably shifts to the cancer itself and its treatment. Patients may not be fully informed about the potential side effects of radiation therapy, which can include skin irritation, fatigue, gastrointestinal issues, and damage to healthy tissues. Consequently, they may not actively seek information about radiation toxicity treatment options that could mitigate these adverse effects.

This lack of awareness can lead to suboptimal patient experiences, as individuals may not be proactive in discussing radiation toxicity concerns with their healthcare providers. As a result, they may endure unnecessary discomfort and a reduced quality of life during their treatment journey.

Key Market Trends

Radioprotective Agents and Supportive Care

Radioprotective agents and supportive care have emerged as powerful drivers boosting the Global Radiation Toxicity Treatment Market. These components of radiation toxicity management are gaining increasing attention and significance in the field of cancer care.

Radioprotective agents are pharmaceuticals and treatments developed to shield healthy tissues from the damaging effects of radiation therapy while simultaneously enhancing the tumor's sensitivity to radiation. These agents are designed to minimize radiation-induced toxicities, making radiation therapy safer and more tolerable for patients. The development of radioprotective drugs represents a major breakthrough, as it allows oncologists to optimize radiation treatment protocols without compromising their efficacy. As a result, patients can receive higher doses of radiation to target cancer cells more effectively while experiencing fewer side effects, driving the demand for such agents and boosting the radiation toxicity treatment market.

Key Market Players

  • Amgen Inc.
  • Jubilant Pharma Limited
  • Tanner Pharma Group
  • Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
  • Recipharm AB
  • Mission Pharmacal Company
  • Partner Therapeutics, Inc.
  • Novartis AG
  • Viatris Inc.
  • Coherus Biosciences Inc

Report Scope:

In this report, the Global Radiation Toxicity Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Radiation Toxicity Treatment Market, By Product:

  • Colony Stimulating Factors
  • Potassium Iodide
  • Prussian Blue Diethylenetriamine Pentaacetic Acid
  • Others

Radiation Toxicity Treatment Market, By Indication:

  • Acute Radiation Syndrome
  • Chronic Radiation Syndrome

Radiation Toxicity Treatment Market, By End-user:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Radiation Toxicity Treatment Market, By Radiation Type:

  • Ionizing Radiation
  • Non-ionizing Radiation

Radiation Toxicity Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Radiation Toxicity Treatment Market.

Available Customizations:

Global Radiation Toxicity Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Radiation Toxicity Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product (Colony Stimulating Factors, Potassium Iodide, Prussian Blue Diethylenetriamine Pentaacetic Acid, Others)
    • 5.2.2. By Indication (Acute Radiation Syndrome, Chronic Radiation Syndrome)
    • 5.2.3. By Radiation Type (Ionizing Radiation, Non-ionizing Radiation)
    • 5.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Radiation Toxicity Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Indication
    • 6.2.3. By Radiation Type
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Radiation Toxicity Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Product
        • 6.3.1.2.2. By Indication
        • 6.3.1.2.3. By Radiation Type
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Radiation Toxicity Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Product
        • 6.3.2.2.2. By Indication
        • 6.3.2.2.3. By Radiation Type
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Radiation Toxicity Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Product
        • 6.3.3.2.2. By Indication
        • 6.3.3.2.3. By Radiation Type
        • 6.3.3.2.4. By End User

7. Europe Radiation Toxicity Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Indication
    • 7.2.3. By Radiation Type
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Radiation Toxicity Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Product
        • 7.3.1.2.2. By Indication
        • 7.3.1.2.3. By Radiation Type
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Radiation Toxicity Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Product
        • 7.3.2.2.2. By Indication
        • 7.3.2.2.3. By Radiation Type
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Radiation Toxicity Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Product
        • 7.3.3.2.2. By Indication
        • 7.3.3.2.3. By Radiation Type
        • 7.3.3.2.4. By End User
    • 7.3.4. France Radiation Toxicity Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Product
        • 7.3.4.2.2. By Indication
        • 7.3.4.2.3. By Radiation Type
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Radiation Toxicity Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Product
        • 7.3.5.2.2. By Indication
        • 7.3.5.2.3. By Radiation Type
        • 7.3.5.2.4. By End User

8. Asia-Pacific Radiation Toxicity Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Indication
    • 8.2.3. By Radiation Type
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Radiation Toxicity Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Product
        • 8.3.1.2.2. By Indication
        • 8.3.1.2.3. By Radiation Type
        • 8.3.1.2.4. By End User
    • 8.3.2. India Radiation Toxicity Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Product
        • 8.3.2.2.2. By Indication
        • 8.3.2.2.3. By Radiation Type
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Radiation Toxicity Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Product
        • 8.3.3.2.2. By Indication
        • 8.3.3.2.3. By Radiation Type
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Radiation Toxicity Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Product
        • 8.3.4.2.2. By Indication
        • 8.3.4.2.3. By Radiation Type
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Radiation Toxicity Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Product
        • 8.3.5.2.2. By Indication
        • 8.3.5.2.3. By Radiation Type
        • 8.3.5.2.4. By End User

9. South America Radiation Toxicity Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Indication
    • 9.2.3. By Radiation Type
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Radiation Toxicity Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Product
        • 9.3.1.2.2. By Indication
        • 9.3.1.2.3. By Radiation Type
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Radiation Toxicity Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Product
        • 9.3.2.2.2. By Indication
        • 9.3.2.2.3. By Radiation Type
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Radiation Toxicity Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Product
        • 9.3.3.2.2. By Indication
        • 9.3.3.2.3. By Radiation Type
        • 9.3.3.2.4. By End User

10. Middle East and Africa Radiation Toxicity Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Product
    • 10.2.2. By Indication
    • 10.2.3. By Radiation Type
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Radiation Toxicity Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Product
        • 10.3.1.2.2. By Indication
        • 10.3.1.2.3. By Radiation Type
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Radiation Toxicity Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Product
        • 10.3.2.2.2. By Indication
        • 10.3.2.2.3. By Radiation Type
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Radiation Toxicity Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Product
        • 10.3.3.2.2. By Indication
        • 10.3.3.2.3. By Radiation Type
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Radiation Toxicity Treatment Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Amgen Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Financials (If Listed)
    • 14.1.5. Key Personnel
    • 14.1.6. SWOT Analysis
  • 14.2. Jubilant Pharma Limited
  • 14.3. Tanner Pharma Group
  • 14.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
  • 14.5. Recipharm AB
  • 14.6. Mission Pharmacal Company
  • 14.7. Partner Therapeutics, Inc.
  • 14.8. Novartis AG
  • 14.9. Viatris Inc.
  • 14.10.Coherus Biosciences Inc.

15. Strategic Recommendations

16. About Us & Disclaimer